A Phase 3 interventional study of Optimized antiparkinsonian treatment and Levodopa-Carbidopa Intestinal Gel (LCIG) in Parkinson's Disease (PD), sponsored by AbbVie. Completed at 28 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2020-08-18.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Parkinson Disease by AbbVie — 6 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · AbbVie.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 13th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2017, is one of 16 in phase 3, and was the 16th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →6 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Croatia and 6 more countries
Ages 18–69
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in Spain
Ages 18+
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Germany
Ages 18–67
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 63 across the 25 interventional studies, 131 across the 18 observational. Of the 33 that completed or were terminated, 18 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
5 of the studies in Parkinson Disease by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07284342AbbVieA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa | 2027-01 |
| NCT05916157AbbVieAn Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | 2027-01 |
| NCT06639620AbbVieStudy To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting | 2027-03 |
| NCT06965374AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease | 2027-06 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Parkinson Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
This was a Phase 3b, open-label, randomized, multicenter, 12-week study. The study consisted of 3 sequential periods: Screening, Treatment, and Follow-Up. The OMT group had the same schedule of visits/procedures throughout the study as the LCIG treatment group, except for visits related to nasojejunal (NJ)/percutaneous endoscopic gastrostomy (PEG) procedures, titration of LCIG, and follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.
Drug: Optimized antiparkinsonian treatment
The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.
Drug: Levodopa-Carbidopa Intestinal Gel (LCIG) · Device: CADD-Legacy ambulatory infusion pump · Device: Percutaneous endoscopic gastrostomy tube · Device: Jejunal extension tube
Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
Dose levels were individually optimized.
Also known as: ABT-SLV187, DUOPA (carbidopa and levodopa Enteral Suspension), DUODOPA
(manufactured by Smiths Medical)
(PEG tube)
(J-tube)
Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score
The Unified Dyskinesia Rating Scale (UDysRS) is a tool used to assess dyskinesia in Parkinson's disease (PD) and contains both self-evaluation questions and items that are assessed directly by the physician to objectively rate the abnormal movements associated with PD. Part 1 contains 11 questions about the ON time dyskinesia and the impact of ON-dyskinesia on experiences of daily living. Part 2 contains 4 questions about OFF-dystonia rating. Part 3 contains 7 questions about objective evaluation of dyskinesia impairment and Part 4 contains 4 questions regarding dyskinesia disability. Each question is scored with respect to severity, which is rated on a scale where 0 = normal, 1 = slight, 2 = mild, 3= moderate and 4 = severe. The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.
Time frame: Baseline, Week 12
Mean Change From Baseline to Week 12 in ON Time Without Troublesome Dyskinesia
The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Positive change from baseline for ON time without troublesome dyskinesia indicates improvement.
Time frame: Baseline, Week 12
Mean Change From Baseline to Week 12 in Parkinson's Disease Questionnaire-8 (PDQ-8) Summary Index
The Parkinson's Disease Questionnaire-8 (PDQ-8) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with PD, and which may not be included in general health status questionnaires. The PDQ-8 is a self-administered questionnaire. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Higher scores are consistently associated with the more severe symptoms of the disease such as tremors and stiffness. The results are presented as a summary index. The PDQ-8 summary index ranges from 0 to 100, where lower scores indicate a better perceived health status. Negative changes from baseline indicate improvement.
Time frame: Baseline, Week 12
Mean Clinical Global Impression of Change (CGI-C) Score at Week 12
The Clinical Global Impression of Change (CGI-C) score is a clinician's rating scale for assessing Global Improvement of Change. The CGI-C rates improvement by 7 categories: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), very much worse (7). The CGI-C score ranges from 1 to 7, with lower scores indicating improvement.
Time frame: Baseline, Week 12
Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living)
The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. Higher scores are associated with more disability. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 12
Mean Change From Baseline to Week 12 in OFF Time
The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Negative change from baseline for OFF time indicates improvement.
Time frame: Baseline, Week 12
Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination)
The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. Higher scores are associated with more disability. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 12
| Milestone | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Started | 33 | 28 |
| Completed | 29 | 25 |
| Not completed | 4 | 3 |
| Withdrew: Withdrew consent | 3 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Participant did not take any study drug | 1 | 0 |
The Unified Dyskinesia Rating Scale (UDysRS) is a tool used to assess dyskinesia in Parkinson's disease (PD) and contains both self-evaluation questions and items that are assessed directly by the physician to objectively rate the abnormal movements associated with PD. Part 1 contains 11 questions about the ON time dyskinesia and the impact of ON-dyskinesia on experiences of daily living. Part 2 contains 4 questions about OFF-dystonia rating. Part 3 contains 7 questions about objective evaluation of dyskinesia impairment and Part 4 contains 4 questions regarding dyskinesia disability. Each question is scored with respect to severity, which is rated on a scale where 0 = normal, 1 = slight, 2 = mild, 3= moderate and 4 = severe. The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.
| units on a scale | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score | -2.33 ± 2.56 | -17.37 ± 2.79 |
The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Positive change from baseline for ON time without troublesome dyskinesia indicates improvement.
| hours | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Mean Change From Baseline to Week 12 in ON Time Without Troublesome Dyskinesia | -0.12 ± 0.63 | 3.15 ± 0.69 |
The Parkinson's Disease Questionnaire-8 (PDQ-8) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with PD, and which may not be included in general health status questionnaires. The PDQ-8 is a self-administered questionnaire. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Higher scores are consistently associated with the more severe symptoms of the disease such as tremors and stiffness. The results are presented as a summary index. The PDQ-8 summary index ranges from 0 to 100, where lower scores indicate a better perceived health status. Negative changes from baseline indicate improvement.
| units on a scale | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Mean Change From Baseline to Week 12 in Parkinson's Disease Questionnaire-8 (PDQ-8) Summary Index | -4.95 ± 3.11 | -21.62 ± 3.47 |
The Clinical Global Impression of Change (CGI-C) score is a clinician's rating scale for assessing Global Improvement of Change. The CGI-C rates improvement by 7 categories: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), very much worse (7). The CGI-C score ranges from 1 to 7, with lower scores indicating improvement.
| units on a scale | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Mean Clinical Global Impression of Change (CGI-C) Score at Week 12 | 4.58 ± 0.25 | 2.48 ± 0.28 |
The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. Higher scores are associated with more disability. Negative values indicate improvement from baseline.
| units on a scale | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living) | 0.21 ± 1.16 | -5.33 ± 1.28 |
The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Negative change from baseline for OFF time indicates improvement.
| hours | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Mean Change From Baseline to Week 12 in OFF Time | 0.18 ± 0.49 | -2.17 ± 0.53 |
The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. Higher scores are associated with more disability. Negative values indicate improvement from baseline.
| units on a scale | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|---|
| Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination) | -0.87 ± 1.89 | -4.93 ± 2.08 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) collection: OMT (starting after the day of randomization until 30 days after the last visit, up to 18 weeks); LCIG group with study tube removal after the last study drug infusion (from the time of tube placement up to 30 days following tube removal, up to 16 weeks); other LCIG participants (starting with tube placement and up to 30 days following the last study visit, up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levodopa-Carbidopa Intestinal Gel (LCIG) | 0/28 (0%) | 2/28 (7.1%) | 15/28 (53.6%) |
| Optimized Medical Treatment (OMT) | 0/33 (0%) | 0/33 (0%) | 4/33 (12.1%) |
| Event | Levodopa-Carbidopa Intestinal Gel (LCIG) | Optimized Medical Treatment (OMT) |
|---|---|---|
| PNEUMOPERITONEUMGastrointestinal disorders | 1/28 | 0/33 |
| CYSTITISInfections and infestations | 1/28 | 0/33 |
| SYNCOPENervous system disorders | 1/28 | 0/33 |
| HYPERTENSIONVascular disorders | 1/28 | 0/33 |
| Event | Levodopa-Carbidopa Intestinal Gel (LCIG) | Optimized Medical Treatment (OMT) |
|---|---|---|
| FALLInjury, poisoning and procedural complications | 6/28 | 2/33 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 3/28 | 0/33 |
| ABDOMINAL PAINGastrointestinal disorders | 2/28 | 0/33 |
| DIARRHOEAGastrointestinal disorders | 2/28 | 0/33 |
| DRUG WITHDRAWAL SYNDROMEGeneral disorders | 2/28 | 0/33 |
| URINARY TRACT INFECTIONInfections and infestations | 2/28 | 0/33 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 2/28 | 0/33 |
| ANXIETYPsychiatric disorders | 2/28 | 0/33 |
| DEPRESSIONPsychiatric disorders | 2/28 | 1/33 |
| PARKINSON'S DISEASENervous system disorders | 1/28 | 2/33 |
Safety Data Set: all participants randomized to OMT and all participants randomized to LCIG treatment who had a study tube (NJ or PEG-J) placement procedure. Two participants randomized to the LCIG arm did not have device placement for LCIG infusion and were not included in the safety data set.
| Age, Continuous(years) | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) | Total |
|---|---|---|---|
| Mean | 68.7 ± 7.20 | 69.3 ± 6.99 | 69.0 ± 7.05 |
| Sex: Female, Male(Participants) | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 17 | 12 | 29 |
| Race/Ethnicity, Customized(Participants) | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) | Total |
|---|---|---|---|
| White | 33 | 28 | 61 |
| Black or African American | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) | Total |
|---|---|---|---|
| Mean | 25.2 ± 4.42 | 24.5 ± 4.24 | 24.9 ± 4.32 |
| Parkinson's disease duration (years)(Participants) | Optimized Medical Treatment (OMT) | Levodopa-Carbidopa Intestinal Gel (LCIG) | Total |
|---|---|---|---|
| < 10 years | 14 | 7 | 21 |
| ≥ 10 years | 19 | 20 | 39 |
| Missing | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Feb 2017 to primary completion in Sep 2019, 31 months.
Results were first posted in Aug 2020, 10 months after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 31 months is close to that.
Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.